Swedish Orphan Biovitrum AB: Sobi and Selecta Biosciences an

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE

Related Keywords

Stockholm , Sweden , China , Boston , Massachusetts , United States , Russia , America , Carsten Brunn , Clin Hypertens , Brittany Leigh , Bruce Mackle , Selecta Biosciences , Selecta Imm , Guido Oelkers , Lifesci Advisors , Lifesci Communications , Selecta Biosciences Inc , Sobi Investor Relations Team , Nasdaq , Chief Executive Officer , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Greater Boston , North America , Middle East , Sobi Media , Sci Advisors , Sci Communications , Swedish , Orphan , Iovitrum , Gobi , Selecta , Iosciences , Nnounce , Completion , Enrolment , Dissolve , Hase , Study , Valuating , Hronic , Refractory , Out ,